Lambert–Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population

ABSTRACT Introduction One nationwide study (The Netherlands) of Lambert–Eaton myasthenic syndrome (LEMS) has been published. We report LEMS epidemiology and its therapeutic response in the United States Veterans Affairs (VA) population. Methods Medical records for all active patients (12.5 million) in the VA health system were queried for relevant ICD‐9 codes for the period October 1, 1999 to September 30, 2013. Clinical, electrophysiologic, and serologic features were evaluated to confirm diagnosis; epidemiologic and treatment data were collected. Results Point prevalence was estimated at 2.6 per 1,000,000 (confirmed cases) and 3.3 per 1,000,000 (combined confirmed and probable cases). Crude prevalence was similarly estimated at 9.2 and 10.9 per 1,000,000 respectively. A total of 18 of 48 (38%) patients received 3,4‐diaminopyridine (3,4‐DAP); 14 of 18 (78%) improved. Conclusions This investigation was a large North American epidemiologic study of LEMS. LEMS prevalence in the national VA population was found to be similar to previously published rates in other large international populations. Most patients experienced improvement with therapy, including a majority with 3,4‐DAP. Muscle Nerve 56: 421–426, 2017